JPS6125710B2 - - Google Patents

Info

Publication number
JPS6125710B2
JPS6125710B2 JP8322479A JP8322479A JPS6125710B2 JP S6125710 B2 JPS6125710 B2 JP S6125710B2 JP 8322479 A JP8322479 A JP 8322479A JP 8322479 A JP8322479 A JP 8322479A JP S6125710 B2 JPS6125710 B2 JP S6125710B2
Authority
JP
Japan
Prior art keywords
dehydropiperidine
oxo
nch
anilino
dione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP8322479A
Other languages
Japanese (ja)
Other versions
JPS567765A (en
Inventor
Yasumitsu Tamura
Rinkei Chin
Masanobu Fujita
Yasuyuki Kita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP8322479A priority Critical patent/JPS567765A/en
Publication of JPS567765A publication Critical patent/JPS567765A/en
Publication of JPS6125710B2 publication Critical patent/JPS6125710B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

【発明の詳細な説明】 本発明は4,4′―メチレンビス―(1―置換―
3―フエニルアミノ―5―オキソ―3,4―デヒ
ドロピペリジン)誘導体およびその塩に関する。 本発明に係る誘導体は新規な化合物であり下記
一般式(1)で表わされる。 〔式中Rはフエニルアルキル基、低級アルカノ
イル基又は低級アルコキシカルボニル基を示す。 上記一般式(1)中Rで示される各基としては具体
的には下記各基を例示できる。 フエニルアルキル基:フエニル基を置換基とし
て有する炭素数1〜4の直鎖状もしくは分枝状ア
ルキル基、例:ベンジル、β―フエネチル、α―
フエネチル、3―フエニルプロピル、4―フエニ
ルブチル基等。 低級アルカノイル基:炭素数1〜4の直鎖状も
しくは分枝状アルカノイル基、例:ホルミル、ア
セチル、プロピオニル、ブチリル、イソブチリル
基等。 低級アルコキシカルボニル基:炭素数1〜4の
直鎖もしくは分枝状アルコキシ基を有するアルコ
キシカルボニル基、例:メトキシカルボニル、エ
トキシカルボニル、プロポキシカルボニル、イソ
プロポキシカルボニル、ブトキシカルボニル、
tert―ブトキシカルボニル基等。 本発明化合物は、例えば下記反応行程式―1に
示す方法に従い製造される。 〔式中Rは上記に同じ。R1及びR2は低級アル
キル基を示す。〕 上記において出発原料とする一般式(2)で表わさ
れるピペリジン―3,5―ジオン誘導体と、アニ
リン(3)との反応は、適当な溶媒例えばメタノー
ル、エタノール等の低級アルコール類又はベンゼ
ン、トルエン等の芳香族炭化水素類中、約50〜
100℃に加熱して行なわれる。アニリン(3)の使用
量は、ピペリジン―3,5―ジオン誘導体(2)に対
し通常等モル〜1.5倍モル程度とするのが好まし
い。上記反応はまた予め誘導体(2)もしくはそのト
リフルオロ酢酸塩に適当な溶媒中でジメチルスル
フイドとN―クロルサクシンイミドとの複合体を
反応後これにアニリン(3)を反応させて行なうこと
ができ、これによれば得られる化合物(4)の収量を
向上させることができる。 かくして得られる化合物(4)と、ホルムアルデヒ
ド(5)及びアミン(6)との反応は、通常のマンニツヒ
反応に準じて容易に実施される。ホルムアルデヒ
ド(5)及びアミン(6)の使用量は、化合物(4)に対し通
常夫々等モル以上好ましくは等モル〜1.5倍モル
程度とするのがよい。この反応は、例えばメタノ
ール、エタノール等の低級アルコール、エーテ
ル、ジオキサン等のエーテル等の溶媒中で有利に
行なわれる。反応温度は特に制限はないが、通常
室温付近とするのが好ましい。また上記反応にお
いては、適当な通常の縮合剤例えば酢酸、炭酸カ
リウム、炭酸ナトリウム、p―トルエンスルホン
酸等を添加するのが好ましく、反応は通常30分〜
数時間で完結する。 本発明の一般式(1)で表わされる4,4′―メチレ
ンビス―(1―置換―3―フエニルアミノ―5―
オキソ―3,4―デヒドロピペリジン)誘導体
は、上記により得られる化合物(7)を、適当な含水
溶媒例えば含水アセトン、含水メタノール、含水
エタノール等の溶媒中、室温下に数時間以上、通
常6〜15時間程度撹拌することにより製造され
る。上記反応は酢酸等の適当な触媒により促進さ
れ得る。 更に本発明の誘導体は、適当な溶媒剤例えば
水、メタノール、エタノール等の低級アルコール
類等の溶媒中で、化合物(4)とホルムアルデヒド(5)
とを加熱反応させることによつても製造できる。 上記反応行程式―1において出発原料として用
いる一般式(2)で表わされるピペリジン―3,5―
ジオン誘導体は、公知化合物〔宮野成二、安倍宜
博、Chem.Pharm.Bull.,20,1588(1972)、F.E.
Ziegler and G.B.Benett,J.Am.Chem.Soc.,
95,7458(1973)〕であるか、之等各文献に記載
の方法に準じて合成することができ、また下記反
応行程式―2に示す如くしても合成できる。 〔式中R3は低級アルカノイル基又は低級アル
コキシカルボニル基およびXは塩素原子または臭
素原子を示す〕 上記反応行程式―2中N―ベンジルピペリジン
―3,5―ジオン(8)の脱ベンジル化反応は、適当
な溶媒中接触還元触媒の存在下に行なわれる。使
用される溶媒としては、水、エーテル、ジオキサ
ン等のエーテル類、メタノール、エタノール等の
低級アルコール類を、また触媒としてはパラジウ
ム炭素、パラジウム黒等を例示できる。上記反応
は通常0℃〜室温下に1〜数時間で行なわれ、こ
れにより一般式(9)で表わされるピペリジン―3,
5―ジオンを得る。 上記ピペリジン―3,5―ジオン(9)と化合物(10)
との反応は、通常のアシル化反応と同様の条件下
に、適当な溶媒中脱酸剤の存在下に行なわれる。
溶媒としては水、エーテル、ジオキサン等のエー
テル類を、また脱酸剤としては炭酸カリウム、炭
酸ナトリウム、炭酸水素ナトリウム等の炭酸塩類
やピリジン等を例示できる。上記反応はまた化合
物(10)に代え、該化合物(10)に対応する酸の無水物
(10)′を用いても行ない得る。化合物(10)またはその
無水物(10)′の使用量は、通常ピペリジン―3,5
―ジオン(9)に対し等モル以上好ましくは等モル〜
1.5倍モル程度とすればよい。また上記反応は0
℃〜室温下に数時間〜15時間程度で行なわれる。 上記反応行程式―1に示す如くして製造される
本発明の誘導体は、医薬的に許容される通常の酸
と反応させて塩の形態とすることができ、本発明
はこの塩の形態の化合物を包含する。上記におい
て用いられる酸としては、例えば塩酸、硫酸、臭
化水素酸、酢酸、蓚酸、マレイン酸、コハク酸、
酒石酸、p―トルエンスルホン酸、メタンスルホ
ン酸等を例示できる。 上記各反応の終了後得られる化合物は、通常の
分離手段例えば溶媒抽出、再結晶、クロマトグラ
フイー等の手段により容易に単離精製できる。 本発明の一般式(1)で表わされる化合物およびそ
の塩は、鎮痛、鎮静、精神安定、解熱、抗ケイレ
ン作用等の中枢神経系に対する薬理作用並びに血
糖低下作用および消炎作用を有しており、鎮痛
剤、鎮静剤、精神安定剤、解熱剤、抗ケイレン
剤、糖尿病治療および消炎剤として有用できる。 以下本発明を更に詳細に説明するために参考例
及び実施例を挙げる。 参考例 1 N―アセチルピペリジン―3,5―ジオンの合
成 N―ベンジルピペリジン―3,5―ジオン6g
への乾燥エーテル100ml懸濁液中に撹拌下に1時
間塩酸ガスを通してN―ベンジルピペリジン―
3,5―ジオン・塩酸塩6.7gを得る(融点170〜
173℃)。 粗N―ベンジルピペリジン―3,5―ジオン・
塩酸塩6.5gを5%パラジウム―カーボン1.63g
の存在下メタノール―水混液(1:1)130ml
中、室温下に数時間接触還元してピペリジン―
3,5―ジオン・塩酸塩3.3gを得る。この塩酸
塩3.2g及び炭酸カリウム4.8gを水10mlに溶かし
た液に、無水酢酸2.9gを滴下する。混合物を室
温下に数時間放置後、10%塩酸11mlで酸性化し、
冷蔵庫内に一夜保持する。析出結晶を取し、熱
時乾燥アセトニトリル20mlで抽出して塩化カリウ
ムを除去し、抽出物を真空濃縮して無色結晶を得
る。 融点:162〜164℃(分解) 収率:65%(N―ベンジルピペリジン―3,
5―ジオンから算出) プロトン核磁気共鳴スペクトル(DMSO―
d6): δ=2.04ppm(s,3H,NCOCH3) =4.08ppm(s,4H,NCH2×2) =5.35ppm(s,1H,CH=) 赤外線吸収スペクトル(KBr錠): ν=1650,1630及び1575cm-1 元素分析値(C7H9NO3として): 理論値(%) C54.19,H5.85,N9.03 実測値(%) C54.09,H5.84,N8.92 参考例 2 N―エトキシカルボニルピペリジン―3,5―
ジオンの合成 N―ベンジルピペリジン―3,5―ジオン800
mgから得たピペリジン―3,5―ジオン・塩酸塩
及び炭酸カリウム886mgを水5mlに溶かした液
に、氷冷下クロロギ酸エチル581mgを添加する。
室温下に3時間撹拌後、反応混合物を10%塩酸3
mlで酸性とし次いでクロロホルムで抽出する。抽
出物を真空濃縮してシロツプを得る。これをクロ
ロホルム―メタノール混液(1:1)を展開溶媒
とするシリカゲルカラムクロマトグラフイーによ
り精製して、N―エトキシカルボニルピペリジン
―3,5―ジオンを得る。 収率:50%(N―ベンジルピペリジン―3,
5―ジオンから算出) プロトン核磁気共鳴スペクトル(CDCl3): δ=1.30ppm(t,3H,J7,NCO2CH2C
H3 ) 4.13ppm(s,4H,NCH2×2) 4.17ppm(quart,2H,J7,NCO2CH2
CH3) 5.56ppm(s,1H,CH=) 6.60ppm(bs,1H,OH) 赤外線吸収スペクトル ν=1615及び1610cm-1 ジオキシムの形態でヘキサンから再結晶後の融
点:59〜60℃ 元素分析値(C9H13NO4として): 理論値(%) C54.27,H6.58,N7.03 実測値(%) C54.16,H6.49,N7.18 参考例 3 1―ベンジル―3―アニリノ―5―オキソ―
3,4―デヒドロピペリジンの合成 〔方法 A〕 N―ベンジルピペリジン―3,5―ジオン100
mg及びアニリン92mgをエタノール10ml中に加えた
混合物を、10時間還流し、真空濃縮して固体を得
る。これをクロロホルム―メタノール混液(5:
1)を溶媒とするシリカゲルカラムクロマトグラ
フイーにより精製して結晶を得る。該結晶をメタ
ノールから再結晶する。 融点:160〜162℃ 収率:20% プロトン核磁気共鳴スペクトル(CDCl3): δ=3.04ppm(s,2H,NCH2) 3.31ppm(s,2H,NCH2) 3.58ppm(s,2H,NCH2C6H5) 5.49ppm(s,1H,CH=) 6.8〜7.4ppm(m,10H,芳香族H) 赤外線吸収スペクトル ν=3400,1610,1585及び1520cm-1 紫外線吸収スペクトル(エタノール): λ=310nm(logε=4.29) 元素分析値(C18H18N2Oとして) 理論値(%) C77.67,H6.52,N10.07 実測値(%) C77.56,H6.53,N10.13 〔方法 B〕 N―ベンジルピペリジン―3,5―ジオン406
mg及びトリフルオロ酢酸228mgを乾燥塩化メチレ
ン4mlに溶かした液を、−20℃下アルゴン雰囲気
下に、別途に調製したN―クロロサクシンイミド
294mgとジメチルスルフイド0.18mlとの乾燥塩化
メチレン20mlの濁つた溶液中に添加する。該溶液
にアニリン280mgを−20℃下に添加し、反応混合
物を徐々に室温に戻し、3時間撹拌し、10%水酸
化ナトリウム水溶液3mlで中性とし、塩化メチレ
ン10mlで4度抽出し、抽出物を飽和塩化ナトリウ
ム水溶液で洗浄し、硫酸マグネシウムで乾燥し、
真空濃縮して固体を得る。これをカラムクロマト
グラフイーで精製して1―ベンジル―3―アニリ
ノ―5―オキソ―3,4―デヒドロピペリジンを
得る。 収率:56% 参考例 4 1―アセチル―3―アニリノ―5―オキソ―
3,4―デヒドロピペリジンの合成 〔方法 A〕 N―アセチルピペリジン―3,5―ジオン620
mg及びアニリン745mgをエタノール20ml中で上記
参考例3〔方法A〕と同様にして反応させて固体
を得、これをメから再結晶して1―アセチル―3
―アニリノ―5―オキソ―3,4―デヒドロピペ
リジンを得る。 融点:211〜212℃ 収率:50% プロトン核磁気共鳴スペクトル(DMSO―d6) δ=2.50ppm(s,3H,CH3CO) 3.32ppm(s,1H,NH) 3.98ppm(s,2H,NCH2) 4.46ppm(s,2H,NCH2) 5.38ppm(s,1H,CH=) 6.95〜7.45ppm(m,5H,芳香族H) 赤外線吸収スペクトル ν=3380,1630,1580及び1540cm-1 紫外線吸収スペクトル(エタノール) λ=308nm(logε=4.34) m/e=230(M+) 元素分析値(C13H14N2O2として) 理論値(%) C67.81,H6.13,N12.17 実測値(%) C67.93,H6.15,N12.24 〔方法 B〕 N―アセチルピペリジン―3,5―ジオン310
mgとアニリン280mgとをトリフルオロ酢酸の不存
在下に反応させて1―アセチル―3―アニリノ―
5―オキソ―3,4―デヒドロピペリジンを得
る。 収率:53% 参考例 5 上記参考例3及び4と同様にして1―エトキシ
カルボニル―3―アニリノ―5―オキソ―3,4
―デヒドロピペリジンを得る。 融点:148〜149℃ プロトン核磁気共鳴スペクトル(CDCl3): δ=1.23ppm(t,3H,OCH2C ) 4.06ppm(s,2H,NCH2) 4.11ppm(quart,2H,OCH2 CH3) 4.44ppm(s,2H,NCH2) 5.60ppm(s,1H,CH=) 7.0〜7.5ppm(m,5H,芳香族H) 7.75ppm(bs,1H,NH) 赤外線吸収スペクトル ν=3380,2970,1680,1600,1580,1540及
び1440cm-1 元素分析値(C14H16N2O3として) 理論値(%) C64.60,H10.76,N6.20 実測値(%) C64.75,H10.66,N6.20 参考例 6 1―ベンジル―3―アニリノ―4―ジエチルア
ミノメチル―5―オキソ―3,4―デヒドロピ
ペリジンの合成 1―ベンジル―3―アニリノ―5―オキソ―
3,4―デヒドロピペリジン27.8mgを、ジエチル
アミン25.6mg、ホルムアルデヒド水溶液(37%)
24.3mg及び酢酸1滴をエタノール1ml中に加えた
溶液中に添加する。混合物を室温下に1.5時間撹
拌し、真空濃縮してシロツプを得る。これをクロ
ロホルムを溶媒とするシリカゲルカラムクロマト
グラフイーにかけ、1―ベンジル―3―アニリノ
―4―ジエチルアミノメチル―5―オキソ―3,
4―デヒドロピペリジンを得る。 収率:73% プロトン核磁気共鳴スペクトル(CDCl3): δ=1.10ppm(t,6H,NCH2C ×2) =2.62ppm(quart,4H,NC 2CH3×
2) =3.10ppm(s,2H,Et2NC ―) =3.55ppm(s,2H,NCH2) =3.61ppm(s,2H,NCH2) =6.50〜7.40ppm(m,10H,芳香族H) =7.95ppm(bs,1H,NH) 赤外線吸収スペクトル: ν=1610,1590及び1575cm-1 ジピクリン酸塩のエタノールから再結晶後の融
点:154〜156℃ 元素分析値(C35H35N9O15として) 理論値(%) C51.16,H4.29,N15.34 理論値(%) C51.04,H4.38,N15.20 参考例 7 1―アセチル―3―アニリノ―4―ジエチルア
ミノメチル―5―オキソ―3,4―デヒドロピ
ペリジンの合成 上記参考例6と同様にして、1―アセチル―3
―アニリノ―5―オキソ―3,4―デヒドロピペ
リジン50mgを、ジエチルアミン56mg、ホルムアル
デヒド水溶液(37%)53mg及び酢酸1滴のエタノ
ール1ml溶液と反応させて、1―アセチル―3―
アニリノ―4―ジエチルアミノメチル―5―オキ
ソ―3,4―デヒドロピペリジンを得る。 収率:70% プロトン核磁気共鳴スペクトル(CDCl3) δ=1.08ppm(t,6H,NCH2C ×2) 2.10ppm(s,3H,CH3CO) 2.58ppm(quart,4H,NC 2CH3×
2) 3.60ppm(s,2H,Et2NCH2―) 4.04ppm(s,2H,NCH2) 4.51ppm(s,2H,NCH2) 6.90〜7.50ppm(m,5H,芳香族H) 9.38ppm(bs,1H,NH) 赤外線吸収スペクトル ν=3360,1640,1600,1590,1580,1500,
1435及び1410cm-1 分光分析データーは上記化合物の提案された構
造式と完全に一致したが、該化合物は比較的不安
定なため充分な分析データーは得られなかつた。 参考例 8 参考例6又は7と同様にして1―エトキシカル
ボニル―3―アニリノ―4―ジエチルアミノメチ
ル―5―オキソ―3,4―デヒドロピペリジンを
得る。 プロトン核磁気共鳴スペクトル(CDCl3): δ=1.06ppm(t,6H,NCH2CH3 ×2) 1.20ppm(t,3H,OCH2 H3 ) 2.54ppm(quart,4H,NCH2 CH3×
2) 3.57ppm(s,2H,Et2NCH2 ) 4.04ppm(s,2H,NCH2) 4.09ppm(quart,2H,CO2CH2 CH3) 4.40ppm(s,2H,NCH2) 6.85〜7.50ppm(m,5H,芳香族H) 9.92ppm(s,1H,NH) 赤外線吸収スペクトル ν=1680,1580,1500,1445,1415及び1385
cm-1 実施例 1 4,4′―メチレンビス―(1―ベンジル―3―
アニリノ―5―オキソ―3,4―デヒドロピペ
リジンの合成 a 1―ベンジル―3―アニリノ―5―オキソ―
3,4―デヒドロピペリジン557mgから得た1
―ベンジル―3―アニリノ―4―ジエチルアミ
ノメチル―5―オキソ―3,4―デヒドロピペ
リジンをアセトン100ml及び水5ml中に溶解す
る。室温下に数分撹拌後、混合物から白色結晶
が析出する。更に10時間撹拌を続け、結晶を集
める。之をエタノールから再結晶して、4,
4′―メチレンビス―(1―ベンジル―3―フエ
ニルアミノ―5―オキソ―3,4―デヒドロピ
ペリジンを得る。 融点:210〜211℃ 収率:70% プロトン核磁気共鳴スペクトル(CDCl3): δ=3.13ppm(s,4H,NCH2×2) 3.47ppm(s,2H,―CH2―C=) 3.57ppm(s,4H,NCH2×2) 6.7〜7.3ppm(m,20H,芳香族H) 10.80ppm(bs,2H,NH×2) 赤外線吸収スペクトル: ν=1620,1580,1490及び1420cm-1 m/e=568(M+) 元素分析値(C37H36N4O2として) 理論値(%) C78.14,H6.38,N9.85 実測値(%) C78.20,H6.42,N9.79 b 1―ベンジル―3―アニリノ―5―オキソ―
3,4―デヒドロピペリジン28mgから得た1―
ベンジル―3―アニリノ―4―ジエチルアミノ
メチル―5―オキソ―3,4―デヒドロピペリ
ジンの溶液と、酢酸1滴を加えたエタノール2
mlとを室温下に3時間撹拌して、4,4′―メチ
レンビス―(1―ベンジル―3―フエニルアミ
ノ―5―オキソ―3,4―デヒドロピペリジン
を得る。 収率:75% c 1―ベンジル―3―アニリノ―5―オキソ―
3,4―デヒドロピペリジン27.8mg及びホルム
アルデヒド水溶液(37%)12mgをエタノール1
mlに加えた液を50時間還流して、4,4′―メチ
レンビス―(1―ベンジル―3―フエニルアミ
ノ―5―オキソ―3,4―デヒドロピペリジン
を得る。 収率:25% 実施例 2〜3 実施例1と同様にして下記各化合物を得る。 実施例2:4,4′―メチレンビス―(1―アセチ
ル―3―アニリノ―5―オキソ―3,
4―デヒドロピペリジン) 融点:239〜241℃(分解) 収率:18% プロトン核磁気共鳴スペクトル(CDCl3): δ=2.09ppm(s,6H,NCOCH3×2) 3.51ppm(s,2H,CH2C=) 4.13ppm(s,4H,NCH2×2) 4.56ppm(s,4H,NCH2×2) 7.1〜7.5ppm(m,10H,芳香族H×
2) 11.10ppm(s,2H,NH) 赤外線吸収スペクトル: ν=1645,1625及び1575cm-1 元素分析値(C27H28N4O4として) 理論値(%) C68.62,H5.97,N11.86 実測値(%) C68.71,H5.93,N11.91 実施例 3 4,4′―メチレンビス―(1―エトキシカルボ
ニル―3―アニリノ―5―オキソ―3,4―デ
ヒドロピペリジン) 融点:244〜245℃ 収率:40% プロトン核磁気共鳴スペクトル(CDCl3): δ=1.23ppm(t,6H,COOCH2CH3 ×
2) 3.53ppm(s,2H,CH2 CH=) 4.16ppm(quart,4H,COOCH2 CH3×
2) 4.16ppm(s,4H,NCH2×2) 4.45ppm(s,4H,NCH2×2) 7.1〜7.5ppm(m,10H,芳香族H×
2) 11.15ppm(s,2H,NH) 赤外線吸収スペクトル: ν=1685及び1575cm-1 元素分析値(C29H32N4O6として) 理論値(%) C65.40,H6.06,N10.52 実測値(%) C65.34,H6.05,N10.45。
DETAILED DESCRIPTION OF THE INVENTION The present invention provides 4,4'-methylenebis-(1-substituted-
3-phenylamino-5-oxo-3,4-dehydropiperidine) derivatives and salts thereof. The derivative according to the present invention is a novel compound and is represented by the following general formula (1). [In the formula, R represents a phenyl alkyl group, a lower alkanoyl group, or a lower alkoxycarbonyl group. Specific examples of each group represented by R in the above general formula (1) include the following groups. Phenyl alkyl group: A linear or branched alkyl group having 1 to 4 carbon atoms having a phenyl group as a substituent, e.g. benzyl, β-phenethyl, α-
Phenethyl, 3-phenylpropyl, 4-phenylbutyl groups, etc. Lower alkanoyl group: A linear or branched alkanoyl group having 1 to 4 carbon atoms, such as formyl, acetyl, propionyl, butyryl, isobutyryl, and the like. Lower alkoxycarbonyl group: an alkoxycarbonyl group having a straight chain or branched alkoxy group having 1 to 4 carbon atoms, examples: methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl,
tert-butoxycarbonyl group, etc. The compound of the present invention can be produced, for example, according to the method shown in Reaction Scheme-1 below. [In the formula, R is the same as above. R 1 and R 2 represent lower alkyl groups. ] In the above, the reaction between the piperidine-3,5-dione derivative represented by general formula (2) and aniline (3), which is used as a starting material, is carried out using a suitable solvent such as lower alcohols such as methanol and ethanol, or benzene and toluene. Approximately 50~ among aromatic hydrocarbons such as
This is done by heating to 100℃. The amount of aniline (3) to be used is preferably about 1 molar to 1.5 times the molar amount of piperidine-3,5-dione derivative (2). The above reaction may also be carried out by reacting the derivative (2) or its trifluoroacetate with a complex of dimethyl sulfide and N-chlorsuccinimide in an appropriate solvent, and then reacting this with aniline (3). According to this, the yield of the obtained compound (4) can be improved. The reaction of the thus obtained compound (4) with formaldehyde (5) and amine (6) is easily carried out according to the usual Mannitz reaction. The amounts of formaldehyde (5) and amine (6) to be used are usually at least equimolar, preferably about equimolar to 1.5 times mole, relative to compound (4). This reaction is advantageously carried out in a solvent such as a lower alcohol such as methanol or ethanol, or an ether such as ether or dioxane. The reaction temperature is not particularly limited, but it is usually preferably around room temperature. In the above reaction, it is preferable to add an appropriate conventional condensing agent such as acetic acid, potassium carbonate, sodium carbonate, p-toluenesulfonic acid, etc., and the reaction is usually carried out for 30 minutes to
It will be completed in a few hours. 4,4'-methylenebis-(1-substituted-3-phenylamino-5-
Oxo-3,4-dehydropiperidine) derivatives are obtained by mixing the compound (7) obtained above in a suitable water-containing solvent, such as water-containing acetone, water-containing methanol, and water-containing ethanol, at room temperature for several hours or more, usually for 6 to 6 hours. Manufactured by stirring for about 15 hours. The above reaction may be accelerated by a suitable catalyst such as acetic acid. Furthermore, the derivative of the present invention can be prepared by combining compound (4) and formaldehyde (5) in a suitable solvent such as water, lower alcohols such as methanol, and ethanol.
It can also be produced by heating and reacting. Piperidine-3,5- represented by general formula (2) used as a starting material in the above reaction scheme-1
Dione derivatives are known compounds [Seiji Miyano, Yoshihiro Abe, Chem.Pharm.Bull., 20, 1588 (1972), FE
Ziegler and G.B.Benett, J.Am.Chem.Soc.
95, 7458 (1973)], or can be synthesized according to the methods described in these documents, or as shown in the following reaction scheme-2. [In the formula, R 3 represents a lower alkanoyl group or a lower alkoxycarbonyl group and X represents a chlorine atom or a bromine atom] Debenzylation reaction of N-benzylpiperidine-3,5-dione (8) in the above reaction scheme-2 is carried out in a suitable solvent in the presence of a catalytic reduction catalyst. Examples of the solvent used include water, ethers such as ether and dioxane, and lower alcohols such as methanol and ethanol, and examples of the catalyst include palladium on carbon and palladium black. The above reaction is usually carried out at 0°C to room temperature for 1 to several hours, and thereby the piperidine-3 represented by the general formula (9),
Obtain 5-Zion. The above piperidine-3,5-dione (9) and compound (10)
The reaction with is carried out in the presence of a deoxidizing agent in a suitable solvent under the same conditions as in a conventional acylation reaction.
Examples of the solvent include water, ether, ethers such as dioxane, and examples of the deoxidizing agent include carbonates such as potassium carbonate, sodium carbonate, and sodium bicarbonate, and pyridine. In the above reaction, instead of compound (10), an acid anhydride corresponding to compound (10) is used.
This can also be done using (10)′. The amount of compound (10) or its anhydride (10)' used is usually piperidine-3,5
-Equimolar or more preferably equimolar to dione (9)
It may be about 1.5 times the mole. Also, the above reaction is 0
It is carried out for several hours to 15 hours at a temperature of ℃ to room temperature. The derivative of the present invention produced as shown in the above reaction scheme-1 can be made into a salt form by reacting with a pharmaceutically acceptable ordinary acid, and the present invention is directed to this salt form. Compounds included. Examples of acids used in the above include hydrochloric acid, sulfuric acid, hydrobromic acid, acetic acid, oxalic acid, maleic acid, succinic acid,
Examples include tartaric acid, p-toluenesulfonic acid, and methanesulfonic acid. The compounds obtained after completion of each of the above reactions can be easily isolated and purified by conventional separation means such as solvent extraction, recrystallization, chromatography and the like. The compound represented by the general formula (1) of the present invention and its salt have pharmacological effects on the central nervous system such as analgesic, sedative, tranquilizing, antipyretic and anti-sedative effects, as well as hypoglycemic and anti-inflammatory effects, It can be useful as an analgesic, sedative, tranquilizer, antipyretic, antidiabetic, antidiabetic, and anti-inflammatory agent. Reference examples and examples are given below to explain the present invention in more detail. Reference example 1 Synthesis of N-acetylpiperidine-3,5-dione 6 g of N-benzylpiperidine-3,5-dione
Hydrochloric acid gas was passed under stirring for 1 hour into a suspension of N-benzylpiperidine in 100 ml of dry ether.
Obtain 6.7 g of 3,5-dione hydrochloride (melting point 170~
173℃). Crude N-benzylpiperidine-3,5-dione
6.5g of hydrochloride and 1.63g of 5% palladium-carbon
130 ml of methanol-water mixture (1:1) in the presence of
After catalytic reduction at room temperature for several hours, piperidine-
3.3 g of 3,5-dione hydrochloride is obtained. 2.9 g of acetic anhydride is added dropwise to a solution of 3.2 g of this hydrochloride and 4.8 g of potassium carbonate dissolved in 10 ml of water. After the mixture was left at room temperature for several hours, it was acidified with 11 ml of 10% hydrochloric acid.
Keep in the refrigerator overnight. The precipitated crystals are collected and extracted with 20 ml of hot dry acetonitrile to remove potassium chloride, and the extract is concentrated in vacuo to obtain colorless crystals. Melting point: 162-164℃ (decomposition) Yield: 65% (N-benzylpiperidine-3,
5-dione) Proton nuclear magnetic resonance spectrum (DMSO-
d 6 ): δ = 2.04ppm (s, 3H, NCOCH 3 ) = 4.08ppm (s, 4H, NCH 2 ×2) = 5.35ppm (s, 1H, CH =) Infrared absorption spectrum (KBr tablet): ν = 1650, 1630 and 1575 cm -1 Elemental analysis values (as C 7 H 9 NO 3 ): Theoretical value (%) C54.19, H5.85, N9.03 Actual value (%) C54.09, H5.84, N8 .92 Reference example 2 N-ethoxycarbonylpiperidine-3,5-
Synthesis of dione N-benzylpiperidine-3,5-dione 800
581 mg of ethyl chloroformate was added to a solution of 886 mg of piperidine-3,5-dione hydrochloride and potassium carbonate obtained from 5 ml of water under ice-cooling.
After stirring at room temperature for 3 hours, the reaction mixture was diluted with 10% hydrochloric acid 3
ml and extracted with chloroform. The extract is concentrated in vacuo to obtain syrup. This is purified by silica gel column chromatography using a chloroform-methanol mixture (1:1) as a developing solvent to obtain N-ethoxycarbonylpiperidine-3,5-dione. Yield: 50% (N-benzylpiperidine-3,
5-dione) Proton nuclear magnetic resonance spectrum (CDCl 3 ): δ=1.30ppm (t, 3H, J7, NCO 2 CH 2 C
H 3 ) 4.13ppm (s, 4H, NCH 2 × 2) 4.17ppm (quart, 2H, J7, NCO 2 C H 2
CH 3 ) 5.56ppm (s, 1H, CH=) 6.60ppm (bs, 1H, OH) Infrared absorption spectrum ν = 1615 and 1610cm -1 Melting point after recrystallization from hexane in the form of dioxime: 59-60°C Elemental analysis Value (as C 9 H 13 NO 4 ): Theoretical value (%) C54.27, H6.58, N7.03 Actual value (%) C54.16, H6.49, N7.18 Reference example 3 1-Benzyl- 3-anilino-5-oxo-
Synthesis of 3,4-dehydropiperidine [Method A] N-benzylpiperidine-3,5-dione 100
A mixture of 92 mg of aniline and 92 mg of aniline in 10 ml of ethanol is refluxed for 10 hours and concentrated in vacuo to give a solid. This was mixed with chloroform-methanol mixture (5:
1) is purified by silica gel column chromatography to obtain crystals. The crystals are recrystallized from methanol. Melting point: 160-162°C Yield: 20% Proton nuclear magnetic resonance spectrum (CDCl 3 ): δ = 3.04ppm (s, 2H, NCH 2 ) 3.31ppm (s, 2H, NCH 2 ) 3.58ppm (s, 2H, NCH 2 C 6 H 5 ) 5.49ppm (s, 1H, CH=) 6.8-7.4ppm (m, 10H, aromatic H) Infrared absorption spectrum ν=3400, 1610, 1585 and 1520 cm -1 Ultraviolet absorption spectrum (ethanol) : λ=310nm (logε=4.29) Elemental analysis value (as C 18 H 18 N 2 O) Theoretical value (%) C77.67, H6.52, N10.07 Actual value (%) C77.56, H6.53 , N10.13 [Method B] N-benzylpiperidine-3,5-dione 406
A solution of 228 mg of trifluoroacetic acid and 228 mg of trifluoroacetic acid dissolved in 4 ml of dry methylene chloride was mixed with separately prepared N-chlorosuccinimide in an argon atmosphere at -20°C.
Add 294 mg of dimethyl sulfide and 0.18 ml of dimethyl sulfide to a cloudy solution of 20 ml of dry methylene chloride. 280 mg of aniline was added to the solution at -20°C, the reaction mixture was gradually warmed to room temperature, stirred for 3 hours, neutralized with 3 ml of 10% aqueous sodium hydroxide solution, and extracted four times with 10 ml of methylene chloride. The material was washed with saturated aqueous sodium chloride solution, dried over magnesium sulfate,
Concentrate in vacuo to obtain a solid. This is purified by column chromatography to obtain 1-benzyl-3-anilino-5-oxo-3,4-dehydropiperidine. Yield: 56% Reference example 4 1-acetyl-3-anilino-5-oxo-
Synthesis of 3,4-dehydropiperidine [Method A] N-acetylpiperidine-3,5-dione 620
mg and 745 mg of aniline in 20 ml of ethanol in the same manner as in Reference Example 3 [Method A] above to obtain a solid, which was recrystallized from 1-acetyl-3
-anilino-5-oxo-3,4-dehydropiperidine is obtained. Melting point: 211-212℃ Yield: 50% Proton nuclear magnetic resonance spectrum (DMSO-d 6 ) δ = 2.50ppm (s, 3H, CH 3 CO) 3.32ppm (s, 1H, NH) 3.98ppm (s, 2H , NCH 2 ) 4.46ppm (s, 2H, NCH 2 ) 5.38ppm (s, 1H, CH=) 6.95-7.45ppm (m, 5H, aromatic H) Infrared absorption spectrum ν=3380, 1630, 1580 and 1540 cm - 1 Ultraviolet absorption spectrum (ethanol) λ = 308 nm (log ε = 4.34) m/e = 230 (M + ) Elemental analysis value (as C 13 H 14 N 2 O 2 ) Theoretical value (%) C67.81, H6.13 , N12.17 Actual value (%) C67.93, H6.15, N12.24 [Method B] N-acetylpiperidine-3,5-dione 310
1-acetyl-3-anilino-
5-oxo-3,4-dehydropiperidine is obtained. Yield: 53% Reference Example 5 1-ethoxycarbonyl-3-anilino-5-oxo-3,4 was prepared in the same manner as in Reference Examples 3 and 4 above.
- Obtain dehydropiperidine. Melting point: 148-149°C Proton nuclear magnetic resonance spectrum ( CDCl3 ): δ = 1.23ppm (t, 3H , OCH2CH3 ) 4.06ppm (s, 2H, NCH2 ) 4.11ppm (quart, 2H , OCH2CH2 ) 2 CH 3 ) 4.44ppm (s, 2H, NCH 2 ) 5.60ppm (s, 1H, CH=) 7.0-7.5ppm (m, 5H, aromatic H) 7.75ppm (bs, 1H, NH) Infrared absorption spectrum ν =3380, 2970, 1680, 1600, 1580, 1540 and 1440 cm -1 Elemental analysis value (as C 14 H 16 N 2 O 3 ) Theoretical value (%) C64.60, H10.76, N6.20 Actual value (% ) C64.75, H10.66, N6.20 Reference example 6 Synthesis of 1-benzyl-3-anilino-4-diethylaminomethyl-5-oxo-3,4-dehydropiperidine 1-benzyl-3-anilino-5- Oxo
3,4-dehydropiperidine 27.8mg, diethylamine 25.6mg, formaldehyde aqueous solution (37%)
24.3 mg and 1 drop of acetic acid are added to a solution of 1 ml of ethanol. The mixture was stirred at room temperature for 1.5 hours and concentrated in vacuo to give a syrup. This was subjected to silica gel column chromatography using chloroform as a solvent, and 1-benzyl-3-anilino-4-diethylaminomethyl-5-oxo-3,
4-dehydropiperidine is obtained. Yield: 73% Proton nuclear magnetic resonance spectrum (CDCl 3 ): δ = 1.10 ppm (t, 6H, NCH 2 CH 3 × 2) = 2.62 ppm (quart, 4H, NC H 2 CH 3 ×
2) = 3.10ppm (s, 2H, Et 2 NC H 2 -) = 3.55ppm (s, 2H, NCH 2 ) = 3.61ppm (s, 2H, NCH 2 ) = 6.50-7.40ppm (m, 10H, aroma Group H) = 7.95 ppm (bs, 1H, NH) Infrared absorption spectrum: ν = 1610, 1590 and 1575 cm -1 Melting point after recrystallization from ethanol of dipicrate: 154-156°C Elemental analysis value (C 35 H 35 As N 9 O 15 ) Theoretical value (%) C51.16, H4.29, N15.34 Theoretical value (%) C51.04, H4.38, N15.20 Reference example 7 1-acetyl-3-anilino-4 -Synthesis of diethylaminomethyl-5-oxo-3,4-dehydropiperidine 1-acetyl-3
-Anilino-5-oxo-3,4-dehydropiperidine (50 mg) was reacted with 56 mg of diethylamine, 53 mg of formaldehyde aqueous solution (37%), and 1 ml of ethanol solution of 1 drop of acetic acid to produce 1-acetyl-3-
Anilino-4-diethylaminomethyl-5-oxo-3,4-dehydropiperidine is obtained. Yield: 70% Proton nuclear magnetic resonance spectrum (CDCl 3 ) δ = 1.08ppm (t, 6H, NCH 2 CH 3 ×2) 2.10ppm (s, 3H , CH 3 CO) 2.58ppm (quart, 4H, NC H 2 CH 3 ×
2) 3.60ppm (s, 2H, Et 2 NCH 2 -) 4.04ppm (s, 2H, NCH 2 ) 4.51ppm (s, 2H, NCH 2 ) 6.90-7.50ppm (m, 5H, aromatic H) 9.38ppm (bs, 1H, NH) Infrared absorption spectrum ν=3360, 1640, 1600, 1590, 1580, 1500,
Although the 1435 and 1410 cm -1 spectroscopic data were completely consistent with the proposed structural formula of the compound, sufficient analytical data could not be obtained due to the relative instability of the compound. Reference Example 8 1-ethoxycarbonyl-3-anilino-4-diethylaminomethyl-5-oxo-3,4-dehydropiperidine is obtained in the same manner as in Reference Example 6 or 7. Proton nuclear magnetic resonance spectrum (CDCl 3 ): δ = 1.06ppm (t, 6H, NCH 2 CH 3 ×2) 1.20ppm (t, 3H, OCH 2 H 3 ) 2.54ppm (quart, 4H, NC H 2 CH 3 ×
2) 3.57ppm (s, 2H, Et 2 NC H 2 ) 4.04ppm (s, 2H, NCH 2 ) 4.09ppm (quart, 2H, CO 2 CH 2 CH 3 ) 4.40ppm (s, 2H, NCH 2 ) 6.85-7.50ppm (m, 5H, aromatic H) 9.92ppm (s, 1H, NH) Infrared absorption spectrum ν=1680, 1580, 1500, 1445, 1415 and 1385
cm -1 Example 1 4,4'-methylenebis-(1-benzyl-3-
Synthesis of anilino-5-oxo-3,4-dehydropiperidine a 1-benzyl-3-anilino-5-oxo-
1 obtained from 557 mg of 3,4-dehydropiperidine
-Benzyl-3-anilino-4-diethylaminomethyl-5-oxo-3,4-dehydropiperidine is dissolved in 100 ml of acetone and 5 ml of water. After stirring for several minutes at room temperature, white crystals precipitate out of the mixture. Continue stirring for an additional 10 hours and collect crystals. Recrystallize this from ethanol, 4.
Obtain 4'-methylenebis-(1-benzyl-3-phenylamino-5-oxo-3,4-dehydropiperidine. Melting point: 210-211°C Yield: 70% Proton nuclear magnetic resonance spectrum ( CDCl3 ): δ= 3.13ppm (s, 4H, NCH 2 ×2) 3.47ppm (s, 2H, -CH 2 -C=) 3.57ppm (s, 4H, NCH 2 ×2) 6.7-7.3ppm (m, 20H, aromatic H ) 10.80ppm (bs, 2H, NH x 2) Infrared absorption spectrum: ν = 1620, 1580, 1490 and 1420cm -1 m/e = 568 (M + ) Elemental analysis value (as C 37 H 36 N 4 O 2 ) Theoretical value (%) C78.14, H6.38, N9.85 Actual value (%) C78.20, H6.42, N9.79 b 1-Benzyl-3-anilino-5-oxo-
1- obtained from 28 mg of 3,4-dehydropiperidine
A solution of benzyl-3-anilino-4-diethylaminomethyl-5-oxo-3,4-dehydropiperidine and ethanol 2 with one drop of acetic acid added.
ml at room temperature for 3 hours to obtain 4,4'-methylenebis-(1-benzyl-3-phenylamino-5-oxo-3,4-dehydropiperidine. Yield: 75% c 1-benzyl -3-anilino-5-oxo-
27.8 mg of 3,4-dehydropiperidine and 12 mg of formaldehyde aqueous solution (37%) were added to 1 part of ethanol.
ml of the solution was refluxed for 50 hours to obtain 4,4'-methylenebis-(1-benzyl-3-phenylamino-5-oxo-3,4-dehydropiperidine. Yield: 25% Example 2~ 3 The following compounds are obtained in the same manner as in Example 1. Example 2: 4,4'-methylenebis-(1-acetyl-3-anilino-5-oxo-3,
4-dehydropiperidine) Melting point: 239-241℃ (decomposition) Yield: 18% Proton nuclear magnetic resonance spectrum (CDCl 3 ): δ = 2.09ppm (s, 6H, NCOCH 3 × 2) 3.51ppm (s, 2H, CH 2 C =) 4.13ppm (s, 4H, NCH 2 × 2) 4.56ppm (s, 4H, NCH 2 × 2) 7.1~7.5ppm (m, 10H, aromatic H ×
2) 11.10ppm (s, 2H, NH) Infrared absorption spectrum: ν = 1645, 1625 and 1575cm -1 Elemental analysis value (as C 27 H 28 N 4 O 4 ) Theoretical value (%) C68.62, H5.97 , N11.86 Actual value (%) C68.71, H5.93, N11.91 Example 3 4,4'-methylenebis-(1-ethoxycarbonyl-3-anilino-5-oxo-3,4-dehydropiperidine ) Melting point: 244-245°C Yield: 40% Proton nuclear magnetic resonance spectrum (CDCl 3 ): δ = 1.23 ppm (t, 6H, COOCH 2 CH 3 ×
2) 3.53ppm (s, 2H, CH 2 CH =) 4.16ppm (quart, 4H, COOC H 2 CH 3 ×
2) 4.16ppm (s, 4H, NCH 2 × 2) 4.45ppm (s, 4H, NCH 2 × 2) 7.1~7.5ppm (m, 10H, aromatic H
2) 11.15ppm (s, 2H, NH) Infrared absorption spectrum: ν = 1685 and 1575cm -1 elemental analysis value (as C 29 H 32 N 4 O 6 ) Theoretical value (%) C65.40, H6.06, N10 .52 Actual value (%) C65.34, H6.05, N10.45.

Claims (1)

【特許請求の範囲】 1 一般式 〔式中Rはフエニルアルキル基、低級アルカノ
イル基又は低級アルコキシカルボニル基を示す〕 で表わされる4,4′―メチレンビス―(1―置換
―3―フエニルアミノ―5―オキソ―3,4―デ
ヒドロピペリジン)誘導体およびその塩。
[Claims] 1. General formula [In the formula, R represents a phenylalkyl group, a lower alkanoyl group, or a lower alkoxycarbonyl group] ) derivatives and their salts.
JP8322479A 1979-06-29 1979-06-29 4,4'-methylenebis-(1-substituted-3-phenylamino-5-oxo-3,4-dehydropiperidine) derivative Granted JPS567765A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP8322479A JPS567765A (en) 1979-06-29 1979-06-29 4,4'-methylenebis-(1-substituted-3-phenylamino-5-oxo-3,4-dehydropiperidine) derivative

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP8322479A JPS567765A (en) 1979-06-29 1979-06-29 4,4'-methylenebis-(1-substituted-3-phenylamino-5-oxo-3,4-dehydropiperidine) derivative

Publications (2)

Publication Number Publication Date
JPS567765A JPS567765A (en) 1981-01-27
JPS6125710B2 true JPS6125710B2 (en) 1986-06-17

Family

ID=13796338

Family Applications (1)

Application Number Title Priority Date Filing Date
JP8322479A Granted JPS567765A (en) 1979-06-29 1979-06-29 4,4'-methylenebis-(1-substituted-3-phenylamino-5-oxo-3,4-dehydropiperidine) derivative

Country Status (1)

Country Link
JP (1) JPS567765A (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI83510C (en) * 1985-02-22 1991-07-25 Ciba Geigy Ag Process for the preparation of novel therapeutically useful bi-2H-pyrroli (di) ndions

Also Published As

Publication number Publication date
JPS567765A (en) 1981-01-27

Similar Documents

Publication Publication Date Title
KR930009793B1 (en) Process for preparing benzopyran derivatives
US4337263A (en) 1-Aryl-4-γ-arylsulphonyl-3-aminopropoxy-1H-pyrazoles and their use as hypolipemiant and hypocholesterolemiant agents
HU200174B (en) Process for producing xanthone derivatives
EP0147805B1 (en) Spiro-linked pyrrolidine-2,5-diones and process for their preparation
JPS61155358A (en) Diallylbutyric acid derivative and production thereof
FR2510115A1 (en) ERGOLINE DERIVATIVES, PROCESS FOR PREPARING THEM AND THEIR USE AS A MEDICINAL PRODUCT
EP0011059B1 (en) Process for the preparation of (+,-) vincadifformine and other related pentacyclic derivatives
KR970002232B1 (en) N-substituted amide derivatives
JPS6125710B2 (en)
AU638878B2 (en) New benzoselenazolinone compounds, process for preparing these and pharmaceutical compositions containing them
JPS634543B2 (en)
JPS6125709B2 (en)
SU718011A3 (en) Method of producing phenylthieno-(2,3-c) piperidine derivatives or salts thereof
JPS6183163A (en) Antitumoral
CA1076577A (en) Process for preparing hydrazinopyridazine derivatives
JPH0480027B2 (en)
CA1300630C (en) 8-piperazinyl-1, 7-naphthyridine derivative
EP0015786B1 (en) Imidazo and pyrimido-pyrido indoles, their preparation and medicines containing them
US4686292A (en) Benzo[α]phenazine antitumor agents
AU697447B2 (en) Propenone derivatives
FR2785903A1 (en) 1-AMINOETHYLQUINOLEINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
EP0002401A1 (en) Derivatives of naphthalene, process for their preparation and their therapeutic application
Assandri et al. Metabolic pathways of the anti-hypertensive agent, N-(2, 5-dimethyl-1H-pyrrol-1-yl)-6-(4-morpholinyl)-3-pyridazinamine hydrochloride. I. Studies in the rat
US4425351A (en) Therapeutically useful oxygen derivatives of 3,7a-diazacyclohepta[j,k]fluorenes
US4647674A (en) Bis-(dibenzo[b,d]pyranyloxy) propanes